These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29049437)

  • 1. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
    JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Mohand-Said S; Cideciyan AV; Birch D; Hariri AH; Nittala MG; Sadda S; Scholl HPN;
    JAMA Ophthalmol; 2017 Jul; 135(7):687-695. PubMed ID: 28542697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11.
    Strauss RW; Kong X; Ho A; Jha A; West S; Ip M; Bernstein PS; Birch DG; Cideciyan AV; Michaelides M; Sahel JA; Sunness JS; Traboulsi EI; Zrenner E; Pitetta S; Jenkins D; Hariri AH; Sadda S; Scholl HPN;
    JAMA Ophthalmol; 2019 Oct; 137(10):1134-1145. PubMed ID: 31369039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
    Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
    Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17).
    Strauss RW; Ho A; Jha A; Fujinami K; Michaelides M; Cideciyan AV; Audo I; Birch DG; Sadda S; Ip M; West S; Schönbach EM; Kong X; Scholl HPN;
    Am J Ophthalmol; 2023 Jun; 250():157-170. PubMed ID: 36764427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
    Schönbach EM; Strauss RW; Muñoz B; Wolfson Y; Ibrahim MA; Birch DG; Zrenner E; Sunness JS; Ip MS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2020 Jul; 138(7):772-779. PubMed ID: 32463436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Genotypic, and Imaging Characterization of the Spectrum of ABCA4 Retinopathies.
    Romano F; Lamanna F; Boon CJF; Siligato A; Kalra G; Agarwal A; Medori C; Bertelli M; Pellegrini M; Invernizzi A; Staurenghi G; Salvetti AP
    Ophthalmol Retina; 2024 May; 8(5):509-519. PubMed ID: 37924945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local progression kinetics of macular atrophy in recessive Stargardt disease.
    Young BK; Zhao PY; Shen LL; Fahim AT; Jayasundera KT
    Ophthalmic Genet; 2023 Dec; 44(6):539-546. PubMed ID: 37381907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
    Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-Specific Lesion Growth Rates in Stargardt Disease.
    Heath Jeffery RC; Thompson JA; Lo J; Lamey TM; McLaren TL; McAllister IL; Constable IJ; De Roach JN; Chen FK
    Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease.
    Cai CX; Light JG; Handa JT
    Am J Ophthalmol; 2018 Feb; 186():1-9. PubMed ID: 29126757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absence of fundus abnormalities in Stargardt disease.
    Bax NM; Lambertus S; Cremers FPM; Klevering BJ; Hoyng CB
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1147-1157. PubMed ID: 30903310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
    Klufas MA; Tsui I; Sadda SR; Hosseini H; Schwartz SD
    Retina; 2018 Feb; 38(2):403-415. PubMed ID: 28248825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1).
    Strauss RW; Muñoz B; Ahmed MI; Bittencourt M; Schönbach EM; Michaelides M; Birch D; Zrenner E; Ervin AM; Charbel Issa P; Kong J; Wolfson Y; Shah M; Bagheri S; West S; Scholl HPN;
    Ophthalmic Res; 2018; 60(3):185-194. PubMed ID: 30110705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
    Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
    Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
    Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
    Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of Visual Acuity and Fundus Autofluorescence in Recent-Onset Stargardt Disease: ProgStar Study Report #4.
    Kong X; West SK; Strauss RW; Munoz B; Cideciyan AV; Michaelides M; Ho A; Ahmed M; Schönbach EM; Cheetham JK; Ervin AM; Scholl HPN;
    Ophthalmol Retina; 2017; 1(6):514-523. PubMed ID: 31047445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into autofluorescence patterns in Stargardt macular dystrophy using ultra-wide-field imaging.
    Kumar V
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1917-1922. PubMed ID: 28689222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Late-Onset Stargardt Disease.
    Lambertus S; Lindner M; Bax NM; Mauschitz MM; Nadal J; Schmid M; Schmitz-Valckenberg S; den Hollander AI; Weber BH; Holz FG; van der Wilt GJ; Fleckenstein M; Hoyng CB;
    Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5186-5191. PubMed ID: 27699414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.